BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27600857)

  • 21. miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma.
    Bao RF; Shu YJ; Hu YP; Wang XA; Zhang F; Liang HB; Ye YY; Li HF; Xiang SS; Weng H; Cao Y; Wu XS; Li ML; Wu WG; Zhang YJ; Jiang L; Dong Q; Liu YB
    Oncotarget; 2016 Apr; 7(16):22339-54. PubMed ID: 26968949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion.
    Imani S; Wei C; Cheng J; Khan MA; Fu S; Yang L; Tania M; Zhang X; Xiao X; Zhang X; Fu J
    Oncotarget; 2017 Mar; 8(13):21362-21379. PubMed ID: 28423483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.
    Shen Y; Ye YF; Ruan LW; Bao L; Wu MW; Zhou Y
    Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways.
    He Q; Ren X; Chen J; Li Y; Tang X; Wen X; Yang X; Zhang J; Wang Y; Ma J; Liu N
    Oncotarget; 2016 Jan; 7(3):3047-58. PubMed ID: 26655091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.
    Wu H; Li J; Guo E; Luo S; Wang G
    Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-181b-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG.
    Yoo JO; Kwak SY; An HJ; Bae IH; Park MJ; Han YH
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1601-11. PubMed ID: 27102539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer.
    Li N; Miao Y; Shan Y; Liu B; Li Y; Zhao L; Jia L
    Cell Death Dis; 2017 May; 8(5):e2796. PubMed ID: 28518139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-503-3p promotes epithelial-mesenchymal transition in breast cancer by directly targeting SMAD2 and E-cadherin.
    Zhao Z; Fan X; Jiang L; Xu Z; Xue L; Zhan Q; Song Y
    J Genet Genomics; 2017 Feb; 44(2):75-84. PubMed ID: 28161325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
    Wang J; Wang S; Zhou J; Qian Q
    Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
    Majumder M; Landman E; Liu L; Hess D; Lala PK
    Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
    Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adipose derived stem cells promote tumor metastasis in breast Cancer cells by stem cell factor inhibition of miR20b.
    Xu H; Li W; Luo S; Yuan J; Hao L
    Cell Signal; 2019 Oct; 62():109350. PubMed ID: 31254605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
    Kong LY; Xue M; Zhang QC; Su CF
    Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells.
    Sathyanarayanan A; Chandrasekaran KS; Karunagaran D
    Cell Oncol (Dordr); 2017 Apr; 40(2):119-131. PubMed ID: 27933466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.
    Wu Z; Li X; Cai X; Huang C; Zheng M
    Tumour Biol; 2016 Jun; 37(6):7939-50. PubMed ID: 26700673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
    Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
    J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-379 inhibits metastasis and epithelial-mesenchymal transition via targeting FAK/AKT signaling in gastric cancer.
    Xu M; Qin S; Cao F; Ding S; Li M
    Int J Oncol; 2017 Sep; 51(3):867-876. PubMed ID: 28713929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. microRNA-335 inhibits colorectal cancer HCT116 cells growth and epithelial-mesenchymal transition (EMT) process by targeting Twist1.
    Wang J; Wang X; Liu F; Fu Y
    Pharmazie; 2017 Aug; 72(8):475-481. PubMed ID: 29441907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA 181b promotes vascular smooth muscle cells proliferation through activation of PI3K and MAPK pathways.
    Li TJ; Chen YL; Gua CJ; Xue SJ; Ma SM; Li XD
    Int J Clin Exp Pathol; 2015; 8(9):10375-84. PubMed ID: 26617745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.